ChromaDex Corporation (CDXC)
- Previous Close
3.4000 - Open
3.4300 - Bid 3.3700 x 100
- Ask 3.4200 x 200
- Day's Range
3.3700 - 3.6500 - 52 Week Range
1.2500 - 4.6500 - Volume
179,435 - Avg. Volume
322,780 - Market Cap (intraday)
256.051M - Beta (5Y Monthly) 1.99
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.47
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
www.chromadex.comRecent News: CDXC
Performance Overview: CDXC
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDXC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDXC
Valuation Measures
Market Cap
256.05M
Enterprise Value
232.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.05
Price/Book (mrq)
9.00
Enterprise Value/Revenue
2.78
Enterprise Value/EBITDA
-59.62
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.91%
Return on Assets (ttm)
-6.42%
Return on Equity (ttm)
-17.29%
Revenue (ttm)
83.57M
Net Income Avi to Common (ttm)
-4.94M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
27.17M
Total Debt/Equity (mrq)
11.52%
Levered Free Cash Flow (ttm)
9.47M